Amgen Korea announced on the 19th that Shin Suhee will be appointed as the new CEO effective the 20th.
CEO Shin has held leadership roles at major multinational pharmaceutical companies and has led the development of business strategies across a wide portfolio in the pharmaceutical industry for over 25 years. This new appointment follows the retirement of CEO Noh Sangkyung, who established Amgen Korea in 2015 and led its business growth.
CEO Shin graduated from Ewha Womans University with a degree in Pharmacy, earned an MBA from New York University’s Stern School of Business, and most recently served as the Head of the Healthcare Innovation Cluster at Roche Korea, where she led portfolio strategy and business performance in oncology, ophthalmology, neuroscience, and infectious diseases. Previously, she was the head of the oncology division at Novartis Korea, focusing on enhancing patient access to innovative therapies and driving talent development and organizational change, achieving high growth rates.
CEO Shin stated, “I am very pleased to lead Amgen Korea, a company driving innovation as a leader in the biotechnology field,” adding, “Under Amgen’s mission of ‘Serving Patients,’ I will work together with Amgen Korea’s employees to continuously provide valuable solutions to patients and healthcare professionals, while striving to establish the company as a responsible and trustworthy organization going forward.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
